Steve Schonfeld’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-15,500
Closed -$49K 3406
2022
Q2
$49K Sell
15,500
-10,600
-41% -$41.3K ﹤0.01% 2226
2022
Q1
$112K Buy
26,100
+10,400
+66% +$45.3K ﹤0.01% 2204
2021
Q4
$73K Hold
15,700
﹤0.01% 1921
2021
Q3
$62K Sell
15,700
-800
-5% -$3.17K ﹤0.01% 1986
2021
Q2
$71K Buy
16,500
+300
+2% +$1.28K ﹤0.01% 1859
2021
Q1
$68K Buy
+16,200
New +$89.3K ﹤0.01% 1704
2018
Q1
Sell
-32,703
Closed -$1.05M 1096
2017
Q4
$1.05M Buy
+32,703
New +$1.07M 0.09% 300
2017
Q3
Sell
-7,255
Closed -$216K 889
2017
Q2
$216K Buy
7,255
+73
+1% +$2.09K 0.02% 542
2017
Q1
$214K Buy
+7,182
New +$183K 0.02% 537

Steve Schonfeld's LJPC Position: Q3 2022 in Review

Steve Schonfeld sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 15,500 shares — an estimated $49K sold.

Steve Schonfeld first reported a position in LJPC in Q1 2017 and held it in 9 quarters. The position peaked at $1.05M in Q4 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

  • Steve Schonfeld reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
  • Steve Schonfeld sold 15,500 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $49K.
  • Steve Schonfeld first reported a position in La Jolla Pharmaceutical Company in Q1 2017 and held it in 9 quarters.
  • Steve Schonfeld's La Jolla Pharmaceutical Company position peaked at $1.05M in Q4 2017.
  • 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.